FilingSEC EDGAR8-K
Voyager Therapeutics Reports Q3 Results and Provides Clinical Pipeline Update
· SEC accepted
StageClinical
Filing content
The company reported a Q3 net loss of $24.7 million, secured cash runway into Q2 2028, and expects clinical data for VY7523 in the fourth quarter.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…